Event Type: Q2 FY27 earnings conference call and investor/analyst meet hosted by Systematix Institutional Equities Limited.

Date and Time: The meeting was held on November 05, 2026 at 04:00 pm. Time zone was not explicitly specified but appears to be IST based on context.

Purpose: Discussion of Q2 FY27 Unaudited Financial Results and business performance update.

Management Participants:

  • Mr. Mark Saldanha – Chairman and Managing Director
  • Mr. Jitendra Sharma – Chief Financial Officer

Moderator: Mr. Vishal Manchanda from Systematix Institutional Equities Limited

Availability of Materials: The transcript of the investor/analyst meet is available on the company website at https://www.marksanspharma.com/earnings-call-transcripts.html

Compliance Statement: The document does not explicitly state whether unpublished price sensitive information (UPSI) would be shared, but it represents a formal regulatory filing of earnings call transcript.

Financial Period Discussed: Q2 FY27 (Second Quarter of Financial Year 2027) and H1 FY27 (First Half of Financial Year 2027)

Financial Highlights:

  • Q2 FY27 Revenue from operations: INR940 crores (30.5% YoY growth)
  • Q2 FY27 EBITDA: INR214 crores (48.3% YoY growth)
  • Q2 FY27 EBITDA margin: 22.8% (274 basis points expansion)
  • Q2 FY27 PAT: INR144 crores (44.8% YoY growth)
  • H1 FY27 Revenue: INR1,781 crores (32.9% growth)
  • H1 FY27 EBITDA: INR427 crores (74.7% growth)
  • H1 FY27 PAT: INR303 crores (92.5% growth)

Geographic Performance Breakdown (Q2 FY27):

  • North America: INR421 crores (44.8% of revenue, 8.7% YoY growth)
  • UK & Europe: INR405 crores (43% of revenue, 65% YoY growth)
  • Australia & New Zealand: INR101 crores (10.7% of revenue, 64% YoY growth)
  • Rest of World: INR14 crores (1.5% of revenue)

Forward-Looking Statements and Strategic Themes:

  • Company targeting INR4,000 crores revenue in FY28 and INR5,000-6,000 crores over 3-5 years
  • US market target: $300 million order book within 3 years (from current $225 million)
  • Australia target: $100 million subsidiary within 3 years
  • Europe target: INR1,000 crores in 5 years
  • Evaluating manufacturing expansion (adding blocks or acquiring plant) within 12 months
  • Considering additional acquisitions in Europe
  • Maintaining EBITDA margin guidance of 21%-22%

Operational Highlights:

  • Gross margin improved 135 basis points YoY to 58.5% in Q2
  • Working capital cycle reduced to 128 days from 138 days in FY26
  • Net cash position: INR1,095 crores as of September end
  • R&D expenditure: 2.6% of revenue in H1
  • Product mix: ~75% OTC, ~25% Rx

Additional Notes Section

The document includes the full transcript of the earnings conference call containing detailed Q&A session with analysts. No financial presentation deck or additional attachments were mentioned in this filing. The announcement primarily serves to disclose the availability of the earnings call transcript as required by SEBI regulations.